**Supplementary Table 1.** HBsAb levels in children before and after the initiation of immunosuppressive therapy (IT)

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | | Healthy children  (N=4889) |  | Group I (N=165)  (HBcAb-/HBcAb-) | | | |  | Group II (N=132)  (HBcAb-/HBcAb+) | | | |
| HBsAb level | 1–14 years |  | Before initiation  of IT |  | After initiation of IT | |  | Before initiation  of IT |  | After initiation of IT | |
| n1=4863 |  |  | 2-month | 10-month |  |  | 2-month | 10-month |
| Titer a (mIU/ml) | 43.2 (6.5, 249.9) |  | 21.7 (2.6, 93.2) |  | 27.5 (9.6, 79.0) | 13.5 (1.2, 27.0) |  | 18.3 (4.9, 109.6) |  | 63.3 (28.1, 129.2) | 12.6 (1.8, 18.2) |
| HBsAb level b | |  |  |  |  |  |  |  |  |  |  |
| [0, 10) | 1493 (29.6) |  | 63 (38.2) |  | 45 (27.3) | 100 (60.6) |  | 48 (36.4) |  | 9 (6.8) | 86 (65.1) |
| [10, 100) | 1605 (33.0) |  | 62 (37.6) |  | 84(50.9) | 44 (26.7) |  | 50 (37.9) |  | 77 (58.3) | 35 (26.5) |
| [100, 1000) | 1174 (24.1) |  | 27 (16.4) |  | 30 (18.2) | 19 (11.5) |  | 25 (18.9) |  | 41 (31.1) | 8 (6.1) |
| >1000 | 645 (13.3) |  | 13 (7.8) |  | 6 (3.6) | 2 (1.2) |  | 9 (6.8) |  | 5 (3.8) | 3 (2.3) |

aData are medians (interquartile range); bData are numbers (%).